-
Your selected country is
Australia
- Change country/language
Old Browser
Looks like you're visiting us from {countryName}.
Would you like to stay on the current country site or be switched to your country?
CD138 APC
Regulatory Status Legend
Any use of products other than the permitted use without the express written authorization of Becton, Dickinson and Company is strictly prohibited.
Preparation And Storage
Store vials at 2°C to 8°C. Conjugated forms should not be frozen. Protect from exposure to light. Each reagent is stable until the expiration date shown on the bottle label when stored as directed.
The CD138 antibody, clone MI15, is derived from the hybridization of SP2/0 mouse myeloma cells with spleen cells isolated from BALB/c mice immunized with human cell line 8266.
The CD138 antibody recognizes syndecan-1, a member of the syndecan family of transmembrane heparin sulfate proteoglycans whose main functions are to modulate ligand-dependent activation of primary signaling receptors at the cell surface. Syndecan-1 exhibits molecular polymorphism| its core protein is a single-chain molecule of 70 to 75 kilodaltons (kDa), and its isoforms vary in molecular weight up to approximately 400 kDa.
Development References (10)
-
Carbone A, Gloghini A, Gattei V, et al. Reed-Sternberg cells of classical Hodgkin's disease react with the plasma cell-specific monoclonal antibody B-B4 and express human syndecan-1. Blood. 1997; 89:3787-3794. (Biology).
-
Carey DJ. Syndecans: multifunctional cell-surface co-receptors. Biochem J. 1997; 327:43846. (Biology).
-
Centers for Disease Control. Update: universal precautions for prevention of transmission of human immunodeficiency virus, hepatitis B virus, and other bloodborne pathogens in healthcare settings. MMWR. 1988; 37:377-388. (Biology).
-
Clinical and Laboratory Standards Institute. 2005. (Biology).
-
Dhodapkar MV, Abe E, Theus A, et al. Syndecan-1 is a multifunctional regulator of myeloma pathobiology: control of tumor cell survival, growth, and bone cell differentiation. Blood. 1998; 91:2679-2688. (Biology).
-
Gaidano G, Gloghini A, Gattei V, et al. Association of Kaposi's sacroma–associated herpes virus–positive primary effusion lymphoma with expression of the CD138/syndecan-1 antigen. Blood. 1997; 90:4894-4900. (Biology).
-
Gattei V, Godeas C, Degan M, Rossi FM, Aldinucci D, Pinto A. Characterization of anti-CD138 monoclonal antibodies as tools for investigating the molecular polymorphism of syndecan-1 in human lymphoma cells. Br J Haematol. 1999; 104(1):152-162. (Biology). View Reference
-
Horvathova M, Gaillard JP, Liautard J, et al. Identification of novel and specific antigens of human plasma cells by mAb. In: Schlossman SF. Stuart F. Schlossman .. et al., ed. Leucocyte typing V : white cell differentiation antigens : proceedings of the fifth international workshop and conference held in Boston, USA, 3-7 November, 1993. Oxford: Oxford University Press; 1995:713-714.
-
Sebestyén A, Berczi L, Mihalik R, Paku S, Matolcsy A, Kopper L. Syndecan-1 (CD138) expression in human non-Hodgkin lymphomas. Br J Haematol. 1999; 104:412-419. (Biology).
-
Wijdenes J, Clément C, Klein B, Dore J-M. CD138 (syndecan-1) Workshop Panel report. In: Kishimoto T. Tadamitsu Kishimoto .. et al., ed. Leucocyte typing VI : white cell differentiation antigens : proceedings of the sixth international workshop and conference held in Kobe, Japan, 10-14 November 1996. New York: Garland Pub.; 1997:249-252.
Please refer to Support Documents for Quality Certificates
Global - Refer to manufacturer's instructions for use and related User Manuals and Technical data sheets before using this products as described
Comparisons, where applicable, are made against older BD Technology, manual methods or are general performance claims. Comparisons are not made against non-BD technologies, unless otherwise noted.
Analyte Specific Reagent. Analytical and performance characteristics are not established.
Analyte Specific Reagent. Analytical and performance characteristics are not established.
Documents are subject to revision without notice. Please verify you have the correct revision of the document, and always refer back to BD's eIFU website for the latest and most up to date information.